Mustang Bio Inc (MBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.20M
Last updated: Nov 17, 2026 at 10:44 AM ET
Mustang Bio Inc (MBIO) Competitors
The companies most similar to Mustang Bio are Creative Medical Technology Holdings (CELZ), PharmaCyte Biotech (PMCB) and Ernexa Therapeutics (ERNA). By market cap, Mustang Bio ranks 7th of the 13 companies on this page; Processa Pharmaceuticals (PCSA) is the largest at $5.20M.
Peer Comparison
MBIO's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Mustang Bio (MBIO) | $3.20M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Creative Medical Technology Holdings Inc (CELZ) | $4.01M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| PharmaCyte Biotech Inc (PMCB) | $3.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Ernexa Therapeutics Inc. (ERNA) | $2.84M | N/A | N/A | 0.0% | N/A | -94.1% | 0.00% |
| Purple Biotech (PPBT) | $2.65M | N/A | N/A | 0.0% | -156.2% | 0.0% | 0.00% |
| Curis Inc (CRIS) | $2.97M | N/A | 1.6x | 0.0% | N/A | -66.0% | 0.00% |
| Revelation Biosciences Inc (REVB) | $2.43M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $4.02M | N/A | N/A | 0.0% | -247.2% | 0.0% | 0.00% |
| CNS Pharmaceuticals Inc (CNSP) | $4.22M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Bioatla Inc (BCAB) | $2.89M | N/A | N/A | 0.0% | N/A | 31.6% | 0.00% |
| Processa Pharmaceuticals Inc (PCSA) | $5.20M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Onconetix Inc (ONCO) | $2.15M | N/A | 1.0x | 0.0% | N/A | -83.9% | 0.00% |
| Traws Pharma Inc (TRAW) | $3.86M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Peer median | $3.37M | N/A | 1.3x | 0.0% | -201.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Mustang Bio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Creative Medical Technology Holdings Inc (CELZ) | Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics... | CELZ competitors |
| PharmaCyte Biotech Inc (PMCB) | PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United... | PMCB competitors |
| Ernexa Therapeutics Inc. (ERNA) | Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. | ERNA competitors |
| Purple Biotech (PPBT) | Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United... | PPBT competitors |
| Curis Inc (CRIS) | Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. | CRIS competitors |
| Revelation Biosciences Inc (REVB) | Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of immunological diagnostics and therapeutics... | REVB competitors |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California. | LIMN competitors |
| CNS Pharmaceuticals Inc (CNSP) | CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central... | CNSP competitors |
| Bioatla Inc (BCAB) | BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapies for the treatment of various cancers. | BCAB competitors |
| Processa Pharmaceuticals Inc (PCSA) | Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients... | PCSA competitors |
| Onconetix Inc (ONCO) | Onconetix Inc. is a cutting-edge biotechnology firm committed to revolutionizing cancer care with its innovative diagnostic and therapeutic solutions. | ONCO competitors |
| Traws Pharma Inc (TRAW) | Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. | TRAW competitors |
Frequently Asked Questions About MBIO
Who are Mustang Bio's main competitors?
The companies most similar to Mustang Bio include Creative Medical Technology Holdings (CELZ), PharmaCyte Biotech (PMCB), Ernexa Therapeutics (ERNA), Purple Biotech (PPBT) and Curis (CRIS), listed from the closest match.
Who is Mustang Bio's biggest competitor?
Processa Pharmaceuticals (PCSA) is the largest of the similar companies at $5.20M; Creative Medical Technology Holdings (CELZ) is the closest match by business profile, size, sector and industry.
How does MBIO stock compare with its competitors?
MBIO's net margin is 0.0% against a peer median of 0.0%.
Which of Mustang Bio's competitors pays a higher dividend?
Mustang Bio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Mustang Bio bigger than its competitors?
No. Mustang Bio is 7th by market cap among the 13 companies on this page; the largest is Processa Pharmaceuticals (PCSA) at $5.20M.
MBIO pages: Overview, Earnings, Financials, Competitors